Vol 10, No 4 (2019)
Review paper
Published online: 2020-04-23

open access

Page views 656
Article views/downloads 1225
Get Citation

Connect on Social Media

Connect on Social Media

Primary immunodeficiency predisposition to the development of lymphoid neoplasms

Justyna Błach1, Agnieszka Bojarska-Junak1, Jacek Roliński1
Hematologia 2019;10(4):179-183.


Primary immunodeficiencies are associated with an increased risk of malignancy. One of the most common immune deficiencies in adults is common variable immunodeficiency — CVID. These patients relatively often develop lymphoproliferative tumours compared to a healthy population. There are cases of the development of this type of cancer in children and young people with CVID without previous symptoms of lymphoid hyperplasia, and even before the diagnosis of immunodeficiency. Therefore, it is important to recognise early symptoms of the disease and imple­ment prompt treatment. The aim of this study was to analyse the mechanisms that may contribute to the development of lymphoid neoplasms in people with CVID. Understanding the immunopatho­genesis of this disease may help to identify future targets for immunotherapy.

Article available in PDF format

View PDF (Polish) Download PDF file


  1. Stray-Pedersen A, Sorte HS, Samarakoon P, et al. Primary immunodeficiency diseases: genomic approaches delineate heterogeneous Mendelian disorders. J Allergy Clin Immunol. 2017; 139(1): 232–245.
  2. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018; 38(1): 96–128.
  3. McCusker C, Upton J, Warrington R, et al. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2011; 7(Suppl 1): S11.
  4. Andrews T, Sullivan KE. Infections in patients with inherited defects in phagocytic function. Clin Microbiol Rev. 2003; 16(4): 597–621.
  5. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009; 22(3): 396–414.
  6. Page AR, Hansen AE, Good RA. Occurrence of leukemia and lymphoma in patients with agammaglobulinemia. Blood. 1963; 21: 197–206.
  7. Salavoura K, Kolialexi A, Tsangaris G, et al. Development of cancer in patients with primary immunodeficiencies. Anticancer Res. 2008; 28(2B): 1263–1269.
  8. Hauck F, Voss R, Urban C, et al. Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. J Allergy Clin Immunol. 2018; 141(1): 59–68.e4.
  9. Bousfiha A, Jeddane L, Picard C, et al. The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. J Clin Immunol. 2018; 38(1): 129–143.
  10. Duan L, Grunebaum E. Hematological malignancies associated with primary immunodeficiency disorders. Clin Immunol. 2018; 194: 46–59.
  11. Riaz IB, Faridi W, Patnaik MM, et al. A systematic review on predisposition to lymphoid (B and T cell) neoplasias in patients with primary immunodeficiencies and immune dysregulatory disorders (inborn errors of immunity). Front Immunol. 2019; 10: 777.
  12. Low LK, Song JY. B-cell lymphoproliferative disorders associated with primary and acquired immunodeficiency. Surg Pathol Clin. 2016; 9(1): 55–77.
  13. Bonilla FA, Bernstein IL, Khan DA, et al. American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005; 94(5 Suppl 1): S1–63.
  14. Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunodeficiencies. J Pediatr. 1995; 126(1): 1–10.
  15. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008; 112(2): 277–286.
  16. Barón-Ruiz I, Martín-Mateos MA, Plaza-Martín AM, et al. Lymphoma as presentation of common variable immunodeficiency. Allergol Immunopathol (Madr). 2009; 37(1): 51–53.
  17. Chua I, Quinti I, Grimbacher B. Lymphoma in common variable immunodeficiency: interplay between immune dysregulation, infection and genetics. Curr Opin Hematol. 2008; 15(4): 368–374.
  18. Vajdic CM, Mao L, van Leeuwen MT, et al. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood. 2010; 116(8): 1228–1234.
  19. Gangemi S, Allegra A, Musolino C. Lymphoproliferative disease and cancer among patients with common variable immunodeficiency. Leuk Res. 2015; 39(4): 389–396.
  20. da Silva SP, Resnick E, Lucas M, et al. Lymphoid proliferations of indeterminate malignant potential arising in adults with common variable immunodeficiency disorders: unusual case studies and immunohistological review in the light of possible causative events. J Clin Immunol. 2011; 31(5): 784–791.
  21. Gompels MM, Hodges E, Lock RJ, et al. Associated Study Group. Lymphoproliferative disease in antibody deficiency: a multi-centre study. Clin Exp Immunol. 2003; 134(2): 314–320.
  22. Roskin KM, Simchoni N, Liu Yi, et al. IgH sequences in common variable immune deficiency reveal altered B cell development and selection. Sci Transl Med. 2015; 7(302): 302ra135.
  23. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001; 2(4): 293–299.
  24. Gao Y, Workman S, Gadola S, et al. Common variable immunodeficiency is associated with a functional deficiency of invariant natural killer T cells. J Allergy Clin Immunol. 2014; 133(5): 1420–8, 1428.e1.
  25. Leng RX, Pan HF, Ye DQ, et al. Potential roles of IL-9 in the pathogenesis of systemic lupus erythematosus. Am J Clin Exp Immunol. 2012; 1(1): 28–32.
  26. Chen J, Petrus M, Bryant BR, et al. Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood. 2010; 116(26): 5948–5956.
  27. Nagato T, Kobayashi H, Kishibe K, et al. Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients. Clin Cancer Res. 2005; 11(23): 8250–8257.
  28. Fischer M, Bijman M, Molin D, et al. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia. 2003; 17(12): 2513–2516.
  29. Lv X, Feng L, Ge X, et al. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma. J Exp Clin Cancer Res. 2016; 35(1): 106.
  30. Rajput S, Wilber A. Roles of inflammation in cancer initiation, progression, and metastasis. Front Biosci (Schol Ed). 2010; 2: 176–183.
  31. Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park). 2011; 25(5): 400–10, 413.
  32. Pietersma F, Piriou E, van Baarle D. Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. Leuk Lymphoma. 2008; 49(6): 1028–1041.
  33. Abolhassani H, Edwards ESJ, Ikinciogullari A, et al. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med. 2017; 214(1): 91–106.
  34. Salzer E, Daschkey S, Choo S, et al. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica. 2013; 98(3): 473–478.
  35. Ghosh S, Bienemann K, Boztug K, et al. Interleukin-2-inducible T-cell kinase (ITK) deficiency — clinical and molecular aspects. J Clin Immunol. 2014; 34(8): 892–899.
  36. Wheat WH, Cool CD, Morimoto Y, et al. Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J Exp Med. 2005; 202(4): 479–484.
  37. Raeiszadeh M, Kopycinski J, Paston SJ, et al. The T cell response to persistent herpes virus infections in common variable immunodeficiency. Clin Exp Immunol. 2006; 146(2): 234–242.
  38. Fliegauf M, Bryant VL, Frede N, et al. Haploinsufficiency of the NF-κB1 subunit p50 in common variable immunodeficiency. Am J Hum Genet. 2015; 97(3): 389–403.
  39. Dornan GL, Burke JE. Molecular mechanisms of human disease mediated by oncogenic and primary immunodeficiency mutations in class IA phosphoinositide 3-kinases. Front Immunol. 2018; 9: 575.
  40. Hildebrand JM, Luo Z, Manske MK, et al. A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J Exp Med. 2010; 207(12): 2569–2579.
  41. Bogaert DJA, Dullaers M, Lambrecht BN, et al. Genes associated with common variable immunodeficiency: one diagnosis to rule them all? J Med Genet. 2016; 53(9): 575–590.
  42. Orange JS, Glessner JT, Resnick E, et al. Genome-wide association identifies diverse causes of common variable immunodeficiency. J Allergy Clin Immunol. 2011; 127(6): 1360–1367.e6.
  43. Ariatti C, Rossi D, Vivenza D, et al. Molecular characterization of common variable immunodeficiency-related lymphomas. Ann Ital Med Int. 2001; 16(3): 163–169.
  44. Zhang Li, Radigan L, Salzer U, et al. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J Allergy Clin Immunol. 2007; 120(5): 1178–1185.
  45. Salzer U, Chapel HM, Webster ADB, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005; 37(8): 820–828.
  46. Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005; 37(8): 829–834.

Hematology in Clinical Practice